Danaher (DHR) closed at $229.03 on Oct 16, 2026, down 1.1% on the day. The stock is up 7.8% over the past month, up 13.9% over three months, up 0.3% year to date and up 11.5% over the past year. It trades 5.5% below its 52-week high of $242.28 and 42.3% above its 52-week low of $160.93. The close sits above its 50-day moving average ($213.90) and above its 200-day moving average ($201.18).
NextPick tracks DHR in its Life Sciences Tools basket alongside TMO, A, WAT, MTD and RVTY. As of Oct 16, 2026, the basket's money-flow score is 7 (neutral), and the basket is up 1.2% over five sessions. Over the past month DHR ranks 3rd of 10 basket members by price change.
DHR is scheduled to report earnings on Oct 21, 2026, before market open. Over its last 8 reports the stock moved an average of 5.1% on the first trading day after earnings, beating the options-implied move in 4 of 8.
DHR options were pricing 43% at-the-money implied volatility on Oct 8, 2026, an IV rank of 100 over the past year.
Danaher is scheduled to report on Oct 21, 2026, before market open.
Over the last 8 reports, DHR moved an average of 5.1% on the first trading day after earnings. The move beat the options-implied move in 4 of 8 reports.
Yes — the Oct 16, 2026 close of $229.03 is 13.8% above the 200-day average of $201.18.
DHR closed 5.5% below its 52-week high of $242.28.
NextPick groups DHR with TMO, A, WAT, MTD and RVTY in its Life Sciences Tools basket.
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
